SCHEMBL20868558

SCHEMBL20868558

CS(=O)(=O)OCc1cc(F)cc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
MMP9 P14780 3/20 0.35
MMP2 P08253 2/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
ACHE P22303 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
CA9 Q16790 4/20 0.34
CA2 P00918 4/20 0.34
GSK3B P49841 2/20 0.34
BACE1 P56817 2/20 0.34
MMP1 P03956 1/20 0.34
MMP12 P39900 1/20 0.34
CA1 P00915 4/20 0.33
CYP4F2 P78329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3942239 0.87 IDO1 (0.37) IDO1MMP9MMP2MMP14ADAM17
SCHEMBL16399039 0.84 IDO1 (0.43) IDO1ALDH1A1KMT2A
SCHEMBL14109586 0.82 HCRTR2 (0.40) IDO1
SCHEMBL778647 0.81 IDO1 (0.55) IDO1MAOB
SCHEMBL31385471 0.81 CA12 (0.42) KDM4EALDH1A1LMNACA9CA2
SCHEMBL4966993 0.81 CA12 (0.42) KDM4EALDH1A1LMNACA9CA2
SCHEMBL10204294 0.80 CYP1A2 (0.34) MMP9KDM4EUSP2ALDH1A1LMNA
SCHEMBL22817377 0.80 CA2 (0.35) MMP9KDM4EUSP2ALDH1A1LMNA
SCHEMBL5033774 0.80 KDM4E (0.41) IDO1MMP9KDM4EUSP2ALDH1A1
SCHEMBL2113033 0.80 TLR7 (0.42) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112055712-A Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2020-12-08 CN claimed
CN-116854630-B Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2026-05-19 CN disclosed
US-20260078123-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF SHANGHAI DAIDAI INVESTMENT CONSULTING CO., LTD (CN) 2026-03-19 US disclosed
US-12516054-B2 Pyrazolo[1,5-a]pyridine derivatives, preparation method therefor and use thereof SHANGHAI DAIDAI INVESTMENT CONSULTING CO., LTD (CN) 2026-01-06 US disclosed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US disclosed
CN-118978537-A Pyrazolo [1,5-a ] pyridine derivative, preparation method and application thereof 上海岱岱投资咨询有限公司 2024-11-19 CN disclosed
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2024-10-22 US disclosed
CN-113508116-B Pyrazolo [1,5-a ] pyridine derivative, preparation method and application thereof 察略盛医药科技(上海)有限公司 2024-08-13 CN disclosed
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2024-03-28 US disclosed
CN-116854630-A Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2023-10-10 CN disclosed
CN-111212830-B N- (substituted sulfonyl) benzamide derivative and preparation method and medical application thereof 浙江海正药业股份有限公司 2023-07-04 CN disclosed
US-20220135560-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF CLUES THERAPEUTICS (SHANGHAI) LTD (CN) 2022-05-05 US disclosed
US-20220009904-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2022-01-13 US disclosed
US-11117886-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2021-09-14 US disclosed
CN-112055712-A Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2020-12-08 CN disclosed
US-20200369647-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2020-11-26 US disclosed
US-10696657-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2020-06-30 US disclosed
US-20190300505-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2019-10-03 US disclosed
CN-109574927-A N- (substituted sulphonyl) benzamide derivatives and preparation method thereof and medical usage 浙江海正药业股份有限公司 2019-04-05 CN disclosed
WO-2019062848-A1 N-(SUBSTITUTED SULFONYL)BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF 浙江海正药业股份有限公司 2019-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300505-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-20220009904-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 IDO1 3240/4885MMP9 2949/4885MMP2 1998/4885
US-20260078123-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF NR3C1, CXCR1, CCR1 IDO1 4380/4885MMP9 4094/4885MMP2 3476/4885
US-11117886-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-10696657-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-20200369647-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 IDO1 3259/4885MMP9 2941/4885MMP2 2024/4885
US-20220135560-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF RET, RIN1, WEE1 IDO1 4042/4885MMP9 4302/4885MMP2 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.